Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
|Articles|April 4, 2022
The Mainstream Patient: April 4
Author(s)Linda Stocum, Associate Editor
This week's edition of the Mainstream Patients features stories about the difference between a sun burn and sun poisoning, micro-coring, and more.
Advertisement
In this week’s edition, Self talks sun poisoning and InStyle talks micro-coring. Martha Stewart dives skin aging and Glamour explains why people may be over-sweating. Elle lists the best tinted moisturizers and Allure explores brands using food waste in skin care.
Here’s What ‘Sun Poisoning’ Actually Means, According to Dermatologists
Meet Micro-Coring, the Non-Invasive Anti-Aging Treatment That Gets Rid of Wrinkles and Loose Skin
At What Age Do Most Women Start to See Changes in Their Skin?
Why Do I Sweat in My Sleep? Here’s What the Experts Say—And How to Solve It
20 Tinted Moisturizers That Are Basically The Paris Filter In A Bottle
These Beauty Brands Are Upcycling Food Waste Into New Products
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5